Clinical Trial

First-in-human Study of HSK56630 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, single ascending dose (SAD) study in healthy adult participants. This is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and PK of HSK56630 in healthy adult participants and preliminarily evaluate the PD of HSK56630.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-25
Trial Details
NCT Number NCT07580794
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Collaborators: Veritus Research Pty Ltd
Conditions Healthy Volunteer
Enrollment 40 participants
Start Date 2026-06-17
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24